Mechanisms of Efficacy of the PAN-FGFR Inhibitor AZD4547 in Pediatric Solid Tumor Models

被引：0
|
作者：
Zage, P. [1 ]
Hakim, S. [1 ]
Subramonian, D. [1 ]
Lesperance, J. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, Pediat, San Diego, CA 92103 USA
来源：
PEDIATRIC BLOOD & CANCER | 2017年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-052
引用
收藏
页码：S137 / S138
页数：2
相关论文
共 50 条
  • [1] Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
    Nikki Phanhthilath
    Sara Hakim
    Catherine Su
    Andrea Liu
    Divya Subramonian
    Jacqueline Lesperance
    Peter E. Zage
    Investigational New Drugs, 2020, 38 : 1677 - 1686
  • [2] Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
    Phanhthilath, Nikki
    Hakim, Sara
    Su, Catherine
    Liu, Andrea
    Subramonian, Divya
    Lesperance, Jacqueline
    Zage, Peter E.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1677 - 1686
  • [3] The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors
    Ma, Q.
    Liao, R.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S687 - S688
  • [4] Evaluation of the pan-FGFR inhibitor AZD4547 with radiation in non-small cell lung cancer
    Miller, Margot
    Fisher, Michael
    Senthilkumar, Gopika
    Kaushik, Saakshi
    Able, Lindsey
    Brennan, Sean
    Iyer, Gopal
    Kimple, Randall
    Baschnagel, Andrew M.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Combining the pan-FGFR inhibitor AZD4547 with radiation in lung and head and neck squamous cell carcinoma
    Baschnagel, Andrew M.
    Li, Chunrong
    Morgan, Alecia M.
    Brennan, Sean R.
    Russo, Kalley A.
    Harari, Paul M.
    CANCER RESEARCH, 2017, 77
  • [6] Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547
    Kas, Sjors M.
    de Ruiter, Julian R.
    Schipper, Koen
    Schut, Eva
    Bombardelli, Lorenzo
    Wientjens, Ellen
    Drenth, Anne Paulien
    de Korte-Grimmerink, Renske
    Mahakena, Sunny
    Phillips, Christopher
    Smith, Paul D.
    Klarenbeek, Sjoerd
    van de Wetering, Koen
    Berns, Anton
    Wessels, Lodewyk F. A.
    Jonkers, Jos
    CANCER RESEARCH, 2018, 78 (19) : 5668 - 5679
  • [7] High efficacy of BAY 1187982, an FGFR2-ADC, in overcoming drug resistance in a diffuse type gastric cancer patient-derived xenograft model with acquired resistance to pan-FGFR inhibitor AZD4547
    Lau, Wen Min
    Teng, Eileen
    Huang, Kie Kyon
    Tan, Jin Wei
    Teh, Ming
    Yong, Wei Peng
    Sommer, Anette
    Schatz, Christoph A.
    Tan, Patrick
    Chan, Shing Leng
    So, Jimmy
    CANCER RESEARCH, 2016, 76
  • [8] The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
    Na, Yu Ran
    Kim, Jin Young
    Song, Chang Ho
    Kim, Mikyung
    Do, Yen Thi
    Vo, Tam Thuy Lu
    Choi, Eunsom
    Ha, Eunyoung
    Seo, Ji Hae
    Shin, So-Jin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [9] Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1
    Zuo-wei Wang
    Feng-ming Zou
    Ao-li Wang
    Jing Yang
    Rui Jin
    Bei-lei Wang
    Li-juan Shen
    Shuang Qi
    Juan Liu
    Jing Liu
    Wen-chao Wang
    Qing-song Liu
    Acta Pharmacologica Sinica, 2023, 44 : 801 - 810
  • [10] Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1
    Wang, Zuo-wei
    Zou, Feng-ming
    Wang, Ao-li
    Yang, Jing
    Jin, Rui
    Wang, Bei-lei
    Shen, Li-juan
    Qi, Shuang
    Liu, Juan
    Liu, Jing
    Wang, Wen-chao
    Liu, Qing-song
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (04): : 801 - 810
12345